# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Inogen (NASDAQ:INGN) with a Hold.
Inogen (NASDAQ:INGN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.55) by 87....
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setti...
Stifel analyst Mathew Blackman maintains Inogen (NASDAQ:INGN) with a Hold and raises the price target from $6 to $7.
Needham analyst Mike Matson reiterates Inogen (NASDAQ:INGN) with a Hold.
Inogen (NASDAQ:INGN) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.76) by 40....